$21.61
0.60% day before yesterday
NYSE, Dec 27, 10:10 pm CET
ISIN
IT0005452658
Symbol
STVN
Industry

Stevanato Group Spa Stock price

$21.61
+1.61 8.05% 1M
+2.88 15.38% 6M
-5.68 20.81% YTD
-5.69 20.84% 1Y
-1.26 5.51% 3Y
+1.94 9.86% 5Y
+1.94 9.86% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.13 0.60%
ISIN
IT0005452658
Symbol
STVN
Industry

Key metrics

Market capitalization $5.89b
Enterprise Value $6.21b
P/E (TTM) P/E ratio 46.74
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.24
P/S ratio (TTM) P/S ratio 4.97
P/B ratio (TTM) P/B ratio 3.99
Dividend yield 0.27%
Last dividend (FY23) $0.06
Revenue growth (TTM) Revenue growth 5.26%
Revenue (TTM) Revenue $1.19b
EBIT (operating result TTM) EBIT $164.42m
Free Cash Flow (TTM) Free Cash Flow $-185.63m
Cash position $87.05m
EPS (TTM) EPS $0.46
P/E forward 47.01
P/S forward 5.12
EV/Sales forward 5.39
Short interest 7.64%
Show more

Is Stevanato Group Spa a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Stevanato Group Spa Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Stevanato Group Spa forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Stevanato Group Spa forecast:

Buy
75%
Hold
25%

Financial data from Stevanato Group Spa

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,186 1,186
5% 5%
100%
- Direct Costs 869 869
12% 12%
73%
317 317
9% 9%
27%
- Selling and Administrative Expenses 33 33
9% 9%
3%
- Research and Development Expense 34 34
3% 3%
3%
249 249
10% 10%
21%
- Depreciation and Amortization 85 85
5% 5%
7%
EBIT (Operating Income) EBIT 164 164
17% 17%
14%
Net Profit 124 124
21% 21%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Stevanato Group Spa directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Stevanato Group Spa Stock News

Positive
Seeking Alpha
about 2 months ago
Q3 2024 sales exceeded estimates, but adj. EBITDA and EPS fell short due to under-utilization and higher costs in the Engineering division. Despite temporary headwinds, we expect sequential margin improvement thanks to high-value solutions and new facilities ramp-up. Long-term growth remains strong, and Stevanato's economic moat remains intact. Looking ahead, we decided to maintain our buy rati...
Neutral
Business Wire
about 2 months ago
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences. The Company will participate in a fireside chat at the UBS Global Healthcare Conference in Rancho Palos...
Neutral
Seeking Alpha
about 2 months ago
Stevanato Group S.p.A. (NYSE:STVN ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Lisa Miles - Senior Vice President & Investor Relations Franco Stevanato - Chairman & Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Larry Solow - CJS Securities Patrick Donnelly - Citi Jacob Johnson - Ste...
More Stevanato Group Spa News

Company Profile

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates in Biopharmaceutical and Diagnostic Solutions and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.

Head office Italy
CEO Franco Stevanato
Founded 1996
Website www.stevanatogroup.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today